Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medifast ( (MED) ) has provided an update.
On March 19, 2026, Medifast Inc. entered into a cooperation agreement with Steamboat Capital Partners, which holds more than 5% of its shares, to reshape its board over the 2026 and 2027 annual meetings. Under the deal, Medifast will nominate Steamboat executives Parsa Kiai and Jeff Rose as independent director candidates at the 2026 shareholder meeting, while incumbent directors Jeffrey Brown and Michael Hoer will not stand for reelection.
The agreement also provides that Kiai and Rose will be nominated again as Steamboat designees at the 2027 meeting, with Steamboat allowed to recommend substitutes if needed, and subjects Steamboat to customary standstill and voting commitments through three months after the 2027 meeting. Announced publicly on March 20, 2026, the pact signals a constructive settlement with an activist investor aimed at strengthening governance, supporting Medifast’s strategic pivot toward metabolic health, and accelerating efforts to restore profitability and unlock long-term shareholder value.
The most recent analyst rating on (MED) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Medifast stock, see the MED Stock Forecast page.
Spark’s Take on MED Stock
According to Spark, TipRanks’ AI Analyst, MED is a Neutral.
MED scores low primarily due to deteriorating operating results (revenue declines, a 2025 loss, and weakened cash generation) and bearish technical trend signals. Valuation metrics are also unfavorable due to the extremely high P/E. Offsetting factors are the strong, low-debt balance sheet and an earnings-call plan focused on cost savings and a late-2026 path toward improved profitability, though execution risk remains high given ongoing demand and coach-count pressures.
To see Spark’s full report on MED stock, click here.
More about Medifast
Medifast Inc., listed on the NYSE as MED, operates in the health and wellness industry with a focus on metabolic health. The company is known for its science-backed, coach-guided lifestyle system that combines personalized plans, scientifically developed products and behavioral frameworks to address metabolic dysfunction. Its model is supported by a large network of independent coaches and underpinned by more than 40 years of clinical heritage.
Medifast has introduced its Metabolic Synchronization science, which targets metabolic reset to reverse metabolic dysfunction and improve body composition. The system aims to reduce visceral fat while preserving lean mass and muscle integrity, aligning with the company’s mission of “Lifelong Transformation, Making a Healthy Lifestyle Second Nature.” This positions Medifast as a differentiated platform in the competitive weight management and metabolic health market.
Average Trading Volume: 252,625
Technical Sentiment Signal: Sell
Current Market Cap: $110.7M
See more insights into MED stock on TipRanks’ Stock Analysis page.